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Alopecia is a non-life-threatening condition, which may seem
trivial to the una¡ected. However, those physicians who see
patients with hair loss know all too well the devastating impact
it can have on an individual’s quality of life. The study of Kantor
et al in this issue of the journal (2003) not only has signi¢cant
implications for dermatology but other areas of biology. While
they show a strong trend for those with alopecia to be at the
low end of the serum ferritin scale, they raise some fascinating
questions about the role of iron in basic biology. Why women
with alopecia have low serum ferritin concentrations is of con-
cern to dermatologists, other groups with an interest in condi-
tions that have rapid cell proliferation should also consider the
implication of a low serum ferritin.While the e¡ect of iron on
blood is relatively well known, its role in other systems is only
just emerging.
Although the association between iron and hair loss was ¢rst
postulated by Hrd (1963), it was not until the early 1990s that the
signi¢cance of low iron stores as assessed by serum ferritin concen-
trations in women with di¡use hair loss (androgenetic alopecia,
AGA) (Rushton et al, 1990) was ¢rst demonstrated (Rushton and
Ramsay, 1992; Rushton and Fenton, 1992). Since then the role of
serum ferritin in female hair loss has been a controversial topic
¢ercely debated at international hair meetings. The report by Kan-
tor et al is the ¢rst study, based on sound epidemiological princi-
ples, to clearly demonstrate an association between low serum
ferritin and alopecia. Some may argue the sample sizes are too
small, but signi¢cant di¡erences were found, adding to the grow-
ing body of evidence that serum ferritin is important in hair biol-
ogy and supporting the largely anecdotal evidence of its role in
persistent excessive hair shedding (chronic telogen e¥uvium,
CTE).Whether a low serum ferritin is causative remains to be seen.
Iron is stored mainly in the liver, within the iron storage pro-
teins ferritin and hemosiderin. Many of the key biological func-
tions of iron in living systems rely on the high redox potential
enabling rapid conversion between Fe2þ and Fe3þ. Iron stimu-
lates the liver to make ferritin, and serum ferritin provides a reli-
able estimate of body iron stores (Cook et al, 1974). The majority
of functional iron within the body is present in haem proteins,
which are involved in oxygen transport and mitochondrial elec-
tron transfer.Total body iron averages approximately 3.8 g in men
and 2.3 g in women. This di¡erence is re£ected in the lower
reference ranges for hemoglobin and serum ferritin in ‘‘normal’’
adult females which we have argued could represent pathological
iron de¢ciency (Rushton et al, 2001). This hypothesis has been
supported by a large-scale US study that found 38% of women
in the San Diego area to be iron de¢cient (Rushton et al, 2002),
con¢rming a problem far more common than many physicians
appreciate. Hobbs (1961), in a di¡erent area of medicine, sug-
gested the ‘‘normal’’ adult female range for hemoglobin was not
physiological and iron therapy should be instituted in all women
with a hemoglobin level below 136 g/L; the current lower limit
is 120 g/L. Kantor et al’s ¢ndings of a signi¢cantly lower hemo-
globin and serum ferritin concentrations in women with telogen
e¥uvium (TE) under the age of 40 compared with controls is
noteworthy.
The deleterious e¡ects of iron de¢ciency are partly due to
impaired delivery of oxygen to the tissues and to a de¢ciency of
iron-containing compounds (Hallberg, 1982). Clinical features
include restlessness and irritability (Dillmann et al, 1979), lower
IQ scores in adolescent girls (Bruner et al, 1996; Nelson, 1999),
fatigue in nonanaemic women (Verdon et al, 2003), and perhaps
more signi¢cant, abnormalities in response to infection and
impaired T-cell proliferation (Dallman, 1986). The latter is parti-
cularly relevant in view of the surprise ¢nding of a signi¢cantly
lower mean serum ferritin concentration in women with alopecia
areata (AA), when they would have been expected to have had
higher values due to AA being regarded as an in£ammatory con-
dition. This certainly raises some interesting questions, not least:
why do those with alopecia totalis/universalis have higher serum
ferritin concentrations? The authors speculate on this observation
and explain their ¢ndings by a ‘‘threshold theory,’’ but further
investigation is needed.Whether increasing the serum ferritin le-
vel will have any meaningful impact on the natural course of AA
or if there is a bene¢cial in£uence on therapeutic regimens needs
to be studied. Further, what are the frequencies of AA,TE, CTE,
and AGA in female patients with iron excess, e.g., hemochroma-
tosis? Clearly, answers to these questions are eagerly awaited.
The importance of the Kantor et al work and the potential im-
pact for female alopecia su¡erers is clear to see. The evidence that
serum ferritin plays an important role in hair loss is becoming
more evident. Any guidance that helps the dermatologist deal
with patients complaining of hair loss is most welcome, as is
understanding the mechanisms involved. The optimal serum
ferritin range in women with alopecia has yet to be established.
While we await this data, it might be prudent to use parameters
obtained from studies of iron staining in the bone marrow, which
suggest a serum ferritin concentration of between 30 and 70 mg/
L, in the absence of in£ammation, would be appropriate. Kantor
et al provide a ¢rm basis for future research and, if their ¢ndings
are con¢rmed, current dermatological practises and investigations
involving therapeutic agents will need to be reviewed.
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